Results 91 to 100 of about 1,158 (177)

Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.

, 2017
OBJECTIVE: To determine safety and pharmacodynamics/efficacy of teduglutide in children with intestinal failure associated with short bowel syndrome (SBS-IF).
Dimmitt, Reed A, Horslen, Simon, Lim, Joel D, Thompson, John, Merritt, Russell J, Cohran, Valeria C, Corkins, Mark R, Vaughan, Juliana F, Hill, Susan, Sigurdsson, Luther, Duggan, Christopher, Mercer, David F, Kocoshis, Samuel A, Li, Benjamin, Teitelbaum, Daniel H, Nichol, Peter F, Carter, Beth A, Youssef, Nader N, Vanderpool, Charles, Venick, Robert S, Cole, Conrad R   +20 more
core   +1 more source

Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study

, 2013
BACKGROUND & AIMS: Short bowel syndrome (SBS)-intestinal failure (IF) patients have impaired quality of life (QoL) and suffer from the burden of malabsorption and parenteral support (PS).
PIRONI, LORIS, Berghöfer P., Youssef NN, Loth S, Heinze H, Forbes A, Jeppesen PB, Joly F, Messing B, Gabe SM, Pertkiewicz M   +10 more
core   +1 more source

Real-life experience of teduglutide use in pediatric patients with short bowel syndrome in Argentina. A multicenter study

Intestinal Failure
Introduction: Current treatment of patients with chronic intestinal failure due to short bowel syndrome (CIF-SBS) attempts to promote the intestinal adaptation process. Teduglutide (TED) is the first successful pharmacological intervention which enhances
María Inés Martínez, Verónica Busoni, Carola Saure, Corina Dlugosewsky, Marcela Dalieri, Sandra Cosentino, Martín Balacco, Lorena Rudi, Adriana Fernandez, Carolina Rumbo   +9 more
doaj   +1 more source

Emerging treatment options for short bowel syndrome: potential role of teduglutide

Clinical and Experimental Gastroenterology, 2011
Cheng T Tee1,2 Katharina Wallis1,3 Simon M Gabe1,41Lennard-Jones Intestinal Failure Unit, St Mark's Hospital and Academic Institute, Harrow, UK; 2Antigen Presentation Research Group, Imperial College London, Northwick Park and St Mark's ...
Gabe SM, Wallis K, Tee CT
doaj  

Malnutrition enteropathy in Zambian and Zimbabwean children with severe acute malnutrition: A multi-arm randomized phase II trial

Nature Communications
Malnutrition underlies almost half of all child deaths globally. Severe Acute Malnutrition (SAM) carries unacceptable mortality, particularly if accompanied by infection or medical complications, including enteropathy. We evaluated four interventions for
Kanta Chandwe, Mutsa Bwakura-Dangarembizi, Beatrice Amadi, Gertrude Tawodzera, Deophine Ngosa, Anesu Dzikiti, Nivea Chulu, Robert Makuyana, Kanekwa Zyambo, Kuda Mutasa, Chola Mulenga, Ellen Besa, Jonathan P. Sturgeon, Shepherd Mudzingwa, Bwalya Simunyola, Lydia Kazhila, Masuzyo Zyambo, Hazel Sonkwe, Batsirai Mutasa, Miyoba Chipunza, Virginia Sauramba, Lisa Langhaug, Victor Mudenda, Simon H. Murch, Susan Hill, Raymond J. Playford, Kelley VanBuskirk, Andrew J. Prendergast, Paul Kelly   +28 more
doaj   +1 more source

Evaluation of the Effectiveness of Teduglutide Treatment in Patients with Short Bowel Syndrome in Slovakia—Multicenter Real-World Study

(1) Background: We present the first real-world-data study on teduglutide-treated SBS patients in the Slovak Republic and the first study to enable the comparison of the effects of teduglutide treatment between the adult and pediatric populations.
Jarmila Hornová, Zuzana Havlíčeková, Barbora Norek, Martina Ondrušová, Laura Gombošová, Martin Suchanský, Iveta Valachová, Juraj Krivuš, Jakub Gazda, Andrea Fojtová, Jana Šprláková   +10 more
core   +1 more source

Add-on to current guidelines for monitoring of SBS patients treated with teduglutide

npj Gut and Liver
By inducing growth of the intestinal epithelium, the drug teduglutide, used for the treatment of short bowel syndrome-associated intestinal failure, could feasibly promote growth of pre-existing colonic neoplasms and incite the development of new ones. A
Francisca Joly, Johane P. Allard, Gabriel E. Gondolesi, Palle Bekker Jeppesen, Martina Kohl-Sobania, Ulrich-Frank Pape, Loris Pironi, Lauren K. Schwartz, Joel Mason   +8 more
doaj   +1 more source

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome

, 2010
Glucagon-like peptide-2 (GLP-2) is a potent intestinotrophic growth factor with therapeutic potential for the prevention or treatment of an expanding number of gastrointestinal diseases, including short bowel syndrome (SBS).
Yazbeck, Roger
core   +1 more source

Teduglutide for short bowel syndrome [PDF]

Australian Prescriber, 2020
openaire   +2 more sources

Successful treatment with teduglutide in short bowel syndrome with intestinal failure secondary to small-bowel volvulus: a case report and literature review. [PDF]

Int J Surg Case Rep
Ito S, Akabane S, Hosoda K, Fujii S.
europepmc   +1 more source